BioVie released encouraging findings from a phase 2 trial of their Parkinson's and Alzheimer's drug

BioVie released encouraging findings from a phase 2 trial of their Parkinson's and Alzheimer's drugПодробнее

BioVie recent announcements around Alzheimers and Parkinson's shows encouraging dataПодробнее

BioVie: Developing the First Ever Potentially Effective Drug for Alzheimer’sПодробнее

BioVie shares latest updates on Alzheimer's and Parkinson's Disease clinical trialsПодробнее

Biovie and Parkinson's DiseaseПодробнее

BioVie: Potential solutions for Alzheimer's, Parkinson'sПодробнее

BioVie Inc. Findings: Enhancing Motor Control in Parkinson's PatientsПодробнее

BioVie: Potential Blockbuster Late-Stage Programs Targeting Alzheimer’s & Parkinson’sПодробнее

BioVie's Novel Approach in the Battle Against Alzheimer's and Parkinson'sПодробнее

Breaking News: CEO Reveals Stunning Results in Alzheimer's & Parkinson's Drug TrialПодробнее

BioVie Pharma: Potential solutions for Alzheimer's, Parkinson'sПодробнее

BioVie Pharma Inc announces NE3107 Phase 2 trial has been fully enrolledПодробнее

Hope for Parkinson's and Alzheimer's Patients: An In-Depth Interview with Cuong Do, CEO of BioVie.Подробнее

Phase II trial of XPro1595 for the treatment of Alzheimer’s diseaseПодробнее

In the Spotlight: BioVie's (NASDAQ: BIVI) Quest to Tackle Alzheimer's, Parkinson's, and MoreПодробнее

Alzheimer's and Parkinson's Disease Conference 2022 - Eisai/Biogen Latest DataПодробнее

BioVie (NASDAQ: BIVI): New solutions for Alzheimer's, Parkinson'sПодробнее

BioVie (NASDAQ: BIVI): Recent Phase 2 Drug Trial Shows Improvement in CognitionПодробнее

BioVie discovers data suggesting its NE3107 molecule could impact biological agingПодробнее